Anti-Human CD19 Antibody
英诺赛图(InnoCyto)的 Anti-Human CD19 Antibody(克隆 4G7) 为鼠源 IgG1 单克隆抗体,靶向 CD19(别名 B4 等),Purified 标记,适用于流式细胞术。提供 100 μg、500 μg、25 μg 规格,目录价 ¥610 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 Anti-Human CD19 Antibody(克隆 4G7) 为鼠源 IgG1 单克隆抗体,靶向 CD19(别名 B4 等),Purified 标记,适用于流式细胞术。提供 100 μg、500 μg、25 μg 规格,目录价 ¥610 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
101101 | 100 μg | ¥814
101102 | 500 μg | ¥2,441
101201 | 100 μg | ¥814
101202 | 500 μg | ¥2,441
108401 | 100 μg | ¥1,085
108402 | 500 μg | ¥2,983
108501 | 100 μg | ¥1,085
108502 | 500 μg | ¥2,983
120401 | 25 μg | ¥610
120402 | 100 μg | ¥1,290
Product Details
Regulatory Status|RUO
Protein Concentration|0.5 mg/mL
Storage & Handling|The antibody solution should be stored between 2°C and 8°C
Recommended Usage|For flow cytometric staining, it is recommended to use less than 0.2 µg of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application
See All Formats|Clone 4G7
Background Information
CD19 is a B cell-specific transmembrane glycoprotein that serves as a central regulator of B cell activation, signaling, and development. It is expressed throughout most stages of B cell differentiation, from early pro-B cells through mature peripheral B cells, but is lost upon terminal differentiation into plasma cells. Because of its broad and consistent expression on B lineage cells, CD19 is widely used as a defining marker of the B cell compartment.
Structurally, CD19 is a type I transmembrane protein with two extracellular immunoglobulin-like domains, a single transmembrane region, and a long cytoplasmic tail. The intracellular domain contains multiple tyrosine residues that become phosphorylated following B cell receptor (BCR) engagement. CD19 functions as part of a larger co-receptor complex that includes CD21 (complement receptor 2), CD81 (TAPA-1), and CD225, which together modulate BCR signaling strength and sensitivity.
Functionally, CD19 acts as a signaling amplifier for the BCR. When antigen binds the BCR, CD19 is rapidly phosphorylated by Src family kinases, creating docking sites for signaling molecules such as PI3K. This lowers the threshold for B cell activation, enhances proliferation, promotes survival, and supports antibody production. Through this role, CD19 helps shape humoral immune responses and ensures efficient activation of B cells in response to antigen, particularly when antigen is present at low concentrations. Unlike many immune receptors, CD19 does not have a well-defined classical ligand. Instead, its activity is regulated through its association with the BCR complex and co-receptors. The CD19-CD21 interaction is functionally linked to recognition of complement-tagged antigens, indirectly coupling innate and adaptive immune signals to enhance B cell responses.
Dysregulation of CD19 signaling contributes to disease. Overactive CD19-mediated signaling has been associated with autoimmune diseases such as systemic lupus erythematosus, where hyperresponsive B cells drive autoantibody production. CD19 is also expressed on the vast majority of B cell malignancies, including B cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia, and many non-Hodgkin lymphomas, making it a critical diagnostic and therapeutic target.
In therapeutics, CD19 is one of the most successful targets in modern immuno-oncology. CD19-directed therapies include monoclonal antibodies, antibody–drug conjugates, bispecific T cell engagers, and chimeric antigen receptor (CAR) T cell therapies, many of which have produced durable remissions in refractory B cell cancers. Beyond cancer, CD19-targeted strategies are being explored to selectively deplete pathogenic B cells in autoimmune disease, underscoring CD19’s central role in both disease biology and therapeutic innovation.
Data Sheets
Human peripheral blood lymphocytes were stained with purified anti-Human CD19 clone 4G7 (color-filled histogram) or isotype control (gray histogram), followed by PE anti-Mouse IgG.
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). Anti-Human CD19 Antibody(120401)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/anti-human-cd19-antibody-120401.html.
TeleVM. (2026, November 12). Anti-Human CD19 Antibody(120401). 产品目录. https://www.suprotek.cn/products/item/anti-human-cd19-antibody-120401.html
@misc{biocsp_item_anti_human_cd19_antibody_120401,
title = {Anti-Human CD19 Antibody(120401)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/anti-human-cd19-antibody-120401.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源